Last reviewed · How we verify
NCT04561804: NAFLD
NAFLD and Liver Fibrosis in Obese Adolescents
trial testing laparoscopic sleeve gastrectomy (LSG) and laparoscopic single anastomosis gastric bypass (LSAGB) in Liver Fibrosis in 100 participants. Completed in 1 December 2019.
1 December 2019
Quick facts
| Lead sponsor | Tel-Aviv Sourasky Medical Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 December 2018 |
| Primary completion | 1 December 2019 |
| Estimated completion | 1 December 2019 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- laparoscopic sleeve gastrectomy (LSG) and laparoscopic single anastomosis gastric bypass (LSAGB)
Conditions studied
- Liver Fibrosis — all drugs for Liver Fibrosis →
- Liver Steatosis — all drugs for Liver Steatosis →
- Weight Loss — all drugs for Weight Loss →
Sponsor
Tel-Aviv Sourasky Medical Center
Who can join
Eligibility, any sex, with Liver Fibrosis or Liver Steatosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease resulting from excessive fat accumulation in the liver. Due to its close association with obesity, it has become the most common liver disease in children in the United States. NAFLD can result in progressive fibrosis and lead to end-stage liver disease. Best practices in management of pediatric NAFLD are not clearly defined. Our aim is to clarify the natural history of NAFLD in obese children after weight loss surgery compare to lifestyle intervention. Our secondary aim is to investigate the added value of elastography for the screening and diagnosis of NASH with fibrosis.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Higher BMI predicts liver fibrosis among obese children and adolescents with NAFLD - an interventional pilot study.
Moran-Lev H, Cohen S, Webb M, Yerushalmy-Feler A, et al · · 2021 · cited 17× · PMID 34479517 · DOI 10.1186/s12887-021-02839-1 -
Efficacy of non-pharmacological treatments in pediatric MASLD: a review of the literature.
Mosca A, Braghini MR, Pietrobattista A, Alisi A, et al · · 2025 · PMID 41311807 · DOI 10.3389/fnut.2025.1667377
Verify or expand the search:
- PubMed search for NCT04561804
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Liver Fibrosis
Currently open trials in the same condition.
- NCT07031089 — City-Hospital Collaboration for Early Detection of Liver Fibrosis in Primary Care: A Secondary Prevention Project in the · recruiting
- NCT06940375 — Incidence of Liver Disease-Related Outcomes in People With HIV · recruiting
- NCT07271576 — Research on the Protective Effects of Phycocyanin Against Liver Fibrosis and Cirrhosis · NA · recruiting
- NCT07069725 — The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Partic · Phase 1 · recruiting
- NCT07122700 — Evaluation of Non-Invasive Tests for Metabolic Liver Disease · recruiting
Other Tel-Aviv Sourasky Medical Center trials
Trials by the same sponsor.
- NCT07380737 — Feasibility and Preliminary Effects of the Walking Tall App for Home-Based Gait Training in Parkinson's Disease: A Pilot · NA · recruiting
- NCT07104136 — Improving Adherence to COPD Treatments in Primary Care · NA · enrolling by invitation
- NCT07327021 — MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC · Phase 2 · recruiting
- NCT07191249 — A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previousl · Phase 2 · not yet recruiting
- NCT07235332 — Assessing Toxic Metal Exposure From Vegetarian/Vegan, Omnivorous, and Low-carb Diets in Israel. · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04561804 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tel-Aviv Sourasky Medical Center
- Last refreshed: 24 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04561804.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing